By Colin Kellaher

Regeneron Pharmaceuticals Inc. (REGN) on Thursday reported positive topline phase 2 data for pozelimab in patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH.

The Tarrytown, N.Y., biotechnology company, said results from initial six-patient cohort show pozelimab reduced the abnormal destruction of red blood cells, known as hemolysis, with patients achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase.

Regeneron said it has initiated the second part of the phase 2 trial, adding that plans for a phase 3 program are underway.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 05, 2019 09:25 ET (14:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.